LX101 / LinXCell Biotechnologies - LARVOL DELTA

In vivo preclinical efficacy of a novel "payload-bearing" peptide LX-101 targeting IGF-1R in Ewing sarcoma (AACR 2026) - "Here, we tested the in vitro and in vivo efficacy of LX-101, a next-generation therapy targeting IGF-1R, which couples a proprietary IGF-1 variant to a cytotoxic MTX payload, as a single agent or in combination with alpelisib (a PI3K inhibitor) and temsirolimus (an mTOR inhibitor) in various ES models. The pharmacodynamic effects were evaluated using a custom tissue microarray (TMA) analysis, using sequential multiplex immunofluorescence of 40 proteins related to the IGF/PI3K/mTOR signaling pathway.Our results indicate that LX-101 exhibits potent single-agent activity in the preclinical setting as an anti-cancer agent for ES, and even stronger activity when combined with agents that inhibit PI3K or mTOR. Collectively, the preclinical efficacy demonstrated provides a strong rationale for advancing LX-101 into clinical trials for ES."

Preclinical • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • IGF1

LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent preclinical anti-tumor activity against multiple cancer types with well-established ties to the IGF-1/IGF-1R pathway (AACR 2024) - "LX-101 consists of a proprietary IGF-1 variant coupled to a cytotoxic methotrexate payload. These results demonstrate that LX-101 has potent preclinical anti-tumor activity against multiple cancer cell lines with well-established ties to the IGF-1/IGF-1R pathway, including with different genetic and epigenetic alterations. These data support further clinical development of LX-101 in IGF-1R-involved cancers. New clinical trials are planned."

Preclinical • Breast Cancer • Ewing Sarcoma • Head and Neck Cancer • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • ERG • EWSR1 • FLI1 • IGF1 • PAX3

LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent anti-tumor activity in Ewing sarcoma animal models and desmoplastic small round cell tumor (AACR 2025) - "LX-101 is a next-generation, targeted therapy directed to the IGF-1R, consisting of a proprietary IGF-1 variant coupled to a cytotoxic methotrexate payload. These results demonstrate that LX-101 has potent anti-tumor activity against ES, in vivo and in vitro, and DSRCT, in vitro, providing a differentiated approach from previous IGF-1R targeting agents. These data support further clinical development of LX-101 in ES, DSRCT, and other IGF-1R-involved cancers. Phase 2 clinical trials are expected to begin in 2025."

Preclinical • Ewing Sarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • EWSR1 • FLI1 • WT1

LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent preclinical anti-tumor activity against multiple cancer types with elevated IGF-1R expression (AACR 2025) - "LX-101 consists of a proprietary IGF-1 variant coupled to a cytotoxic methotrexate payload. These results demonstrate that LX-101 has potent preclinical anti-tumor activity against multiple cancer cell lines expressing IGF-1R. These data support further clinical development of LX-101 in IGF-1R-involved cancers. New clinical trials are planned."

Preclinical • Breast Cancer • Esophageal Cancer • Ewing Sarcoma • Gastric Cancer • Lung Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • IGF1

A novel CD20-conjugated γδ T cell therapy via unnatural sugar-mediated chemical modification for the treatment of EBV-PTLD (ASH 2025) - "In vitro, the CD20antibody-conjugated γδ T (CD20-γδ T) cells were co-cultured with EBV and CD20-positive targets,including EBV-transformed lymphoblastoid cell lines (EBV-LCLs), Raji cells, rituximab-resistant Raji cells,and primary EBV-PTLD patient-derived cells... We developed a novel off-the-shelf CD20-γδ T cell therapy using MGL-based ACCtechnology, effectively combining the innate antitumor activity of γδ T cells with the precision of CD20targeting. This approach exhibits potent efficacy against EBV-PTLD in vitro and in vivo, offering apromising allogeneic immunotherapy for refractory EBV-associated diseases."

Epstein-Barr Virus Infections • Solid Organ Transplantation • CD20